UCB S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UCB.BR research report →
About the company
UCB S. A. , a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases.
- CEO
- Jean-Christophe Tellier
- IPO
- 2000
- Employees
- 9,052
- HQ
- Brussels, BE
Price Chart
- Market Cap
- $48.54B
- P/E
- 31.10
- P/S
- 6.27
- P/B
- 4.46
- EV/EBITDA
- 27.07
- Div Yield
- 0.57%
- Gross Margin
- 74.29%
- Op Margin
- 25.32%
- Net Margin
- 20.13%
- ROE
- 15.16%
- ROIC
- 12.13%
- Revenue
- $7.74B · 25.83%
- Net Income
- $1.56B · 46.29%
- EPS
- $8.20 · 46.17%
- Op Income
- $1.17B
- FCF YoY
- 104.57%
- 52W High
- $289.50
- 52W Low
- $162.70
- 50D MA
- $247.12
- 200D MA
- $246.76
- Beta
- 0.18
- Avg Volume
- 252.16K
Get TickerSpark's AI analysis on UCB.BR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our UCB.BR coverage
Recent articles, reports, and earnings notes.
No research on UCB.BR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UCB.BR report →Similar companies
Peers in the same neighborhood.